Batavia Biosciences receives NIIMBL grant to improve AAV Manufacturing

• Batavia Biosciences has partnered with ChromaTan, Inc. to integrate BioRMB technology into Batavia’s AAV HIP-Vax manufacturing platform.

• The project is backed by the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) and the U.S. Department of Commerce, National Institute of Standards and Technology.

Batavia Biosciences, a contract development and manufacturing organisation (CDMO), has announced a strategic partnership with ChromaTan, Inc. The collaboration is focused on the development and integration of BioRMB technology, formerly known as Continuous Countercurrent Tangential Chromatography (CCTC), into Batavia’s AAV HIP-Vax manufacturing platform.

Recombinant adeno-associated virus (rAAV) vectors are at the forefront of developing next-generation treatments for debilitating and life-threatening disorders.

Continuous chromatography has been demonstrated to significantly contribute to the intensification of manufacturing processes for monoclonal antibodies. By integrating ChromaTan’s BioRMB, a novel column-free real moving bed continuous chromatography platform, into Batavia’s proprietary HIP-Vax manufacturing platform, Batavia Biosciences expects to increase its rAAV production capacity.

Oleg Shinkazh, Chief Technical Officer at ChromaTan, said, “The promise of next-generation platforms both upstream and downstream in the field of gene therapy is very powerful for multiple reasons such as improvements in manufacturability, process economics, improved recovery and product quality. This exciting partnership enabled by NIIMBL, will empower us to take that idea a step further – by directly integrating these hyper-efficient next-generation platforms we have the potential to transform rAAV manufacturing as we know it.”

Peter Abbink, Managing Director at Batavia Biosciences, Inc., echoed this sentiment, stating, “At Batavia, we continuously seek innovative solutions to fuel our mission to enhance the accessibility and availability of critical life-changing treatments. We are privileged to have the backing of NIIMBL and are thrilled to embark on a productive partnership with ChromaTan on this endeavour.”

This project was developed with an award from the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) and financial assistance from the U.S. Department of Commerce, National Institute of Standards and Technology.